Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2016-08-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Group A: Included 50 women who will be given clomiphene citrate 50mg (clomid) orally 2 times/day from 2rd-7th day of the cycle and sildeaynafil citrate 20mg tab from 7th-11th day of the same cycle orally 3 times/day.
Group B: Included 50 women who will be given clomiphene citrate 50mg (clomid) orally 2 times/day from 2rd-7th day of the cycle and placebo tablets from 7th-11th day of the same cycle orally 3 times/day.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene
NCT02663830
Effect of Oral Sildenafil Citrate on Improvement of Endometrial Thickness
NCT05846906
Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate in Infertile Women With Thin Endometrium
NCT02710981
Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss
NCT04718233
Effect of Sildenafil Citrate Compared to Estrogen as Adjuvant Therapy for Unexplained Infertility
NCT05753098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group A: Included 50 women who will be given clomiphene citrate 50mg (clomid) orally 2 times/day from 2rd-7th day of the cycle and sildeaynafil citrate 20mg tab from 7th-11th day of the same cycle orally 3 times/day.
Group B: Included 50 women who will be given clomiphene citrate 50mg (clomid) orally 2 times/day from 2rd-7th day of the cycle and placebo tablets from 7th-11th day of the same cycle orally 3 times/day.
Folliculometry was assessed by:
* Transvaginal ultrasound: It was done on day 11th of the cycle to detect number of follicles and endometrial thickness.
When the follicles reach ≥18 ml, injection of 5000 IU of HCG IM to trigger ovulation to both groups.
Pregnancy was assessed by:
* Beta HCG test: (Radioimmunoassay)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sildenafil citrate
50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd - 7th day of the cycle and sildenafil citrate 20mg tab from 7th-11th day of the same cycle orally 3times/day
Clomiphene citrate
50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
sildenafil citrate
20mg tab from 7th-11th day of the same cycle orally 3times/day
placebo group
50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd- 7th day of the cycle and placebo tablets from 7th-11th day of the same cycle orally 3 times/day
Clomiphene citrate
50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
Placebo
tab from 7th-11th day of the same cycle orally 3times/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clomiphene citrate
50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
sildenafil citrate
20mg tab from 7th-11th day of the same cycle orally 3times/day
Placebo
tab from 7th-11th day of the same cycle orally 3times/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Woman's age: (18-35 years old)
3. Menstrual cycle from (24-35 days)
4. Normal semen analysis
Exclusion Criteria
2. Ovarian cysts
3. Abnormal hormonal profile (e.g hyperprolactinaemia)
4. Significant cardiovascular disease
5. Serious liver disease or renal failure
6. Poorly controlled diabetes mellitus
18 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed M Maged, MD
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed Maged
Role: PRINCIPAL_INVESTIGATOR
Kasr Alainy medical school
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr Alainy medical school
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
156
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.